DZ3009A1 - Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents
Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.Info
- Publication number
- DZ3009A1 DZ3009A1 DZ000021A DZ000021A DZ3009A1 DZ 3009 A1 DZ3009 A1 DZ 3009A1 DZ 000021 A DZ000021 A DZ 000021A DZ 000021 A DZ000021 A DZ 000021A DZ 3009 A1 DZ3009 A1 DZ 3009A1
- Authority
- DZ
- Algeria
- Prior art keywords
- derivatives
- preparation
- pharmaceutical compositions
- compositions containing
- heteroaryl substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11970299P | 1999-02-11 | 1999-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ3009A1 true DZ3009A1 (fr) | 2004-03-27 |
Family
ID=22385869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ000021A DZ3009A1 (fr) | 1999-02-11 | 2000-02-09 | Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
Country Status (39)
Country | Link |
---|---|
US (3) | US6258824B1 (fr) |
EP (1) | EP1150973B1 (fr) |
JP (3) | JP4090200B2 (fr) |
KR (1) | KR20010102073A (fr) |
CN (1) | CN1340051A (fr) |
AP (1) | AP2001002241A0 (fr) |
AR (1) | AR028985A1 (fr) |
AT (1) | ATE297916T1 (fr) |
AU (1) | AU2124800A (fr) |
BG (1) | BG105860A (fr) |
BR (1) | BR0008202A (fr) |
CA (1) | CA2362394C (fr) |
CO (1) | CO5140097A1 (fr) |
CZ (1) | CZ20012910A3 (fr) |
DE (1) | DE60020812T2 (fr) |
DZ (1) | DZ3009A1 (fr) |
EA (1) | EA200100766A1 (fr) |
EE (1) | EE200100425A (fr) |
ES (1) | ES2243228T3 (fr) |
GT (1) | GT200000014A (fr) |
HK (1) | HK1042096A1 (fr) |
HN (1) | HN2000000019A (fr) |
HR (1) | HRP20010574A2 (fr) |
HU (1) | HUP0105231A3 (fr) |
ID (1) | ID29584A (fr) |
IL (1) | IL144307A0 (fr) |
IS (1) | IS5997A (fr) |
MA (1) | MA26718A1 (fr) |
NO (1) | NO20013909L (fr) |
OA (1) | OA11833A (fr) |
PA (1) | PA8490601A1 (fr) |
PE (1) | PE20001464A1 (fr) |
PL (1) | PL349839A1 (fr) |
SK (1) | SK11002001A3 (fr) |
SV (1) | SV2001000020A (fr) |
TN (1) | TNSN00028A1 (fr) |
TR (2) | TR200201297T2 (fr) |
WO (1) | WO2000047574A1 (fr) |
ZA (1) | ZA200106520B (fr) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL140721A0 (en) * | 1998-07-06 | 2002-02-10 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
TR200201297T2 (tr) * | 1999-02-11 | 2002-06-21 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. |
US7053117B2 (en) * | 2001-05-16 | 2006-05-30 | Cytovia, Inc. | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU781986B2 (en) * | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
DK1106612T3 (da) * | 1999-11-30 | 2004-05-17 | Pfizer Prod Inc | Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
CA2396593A1 (fr) * | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Traitement ou prevention du cancer de la prostate avec un medicament inhibiteur selectif de cox-2 |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
EP1170011A1 (fr) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Nouvelle utilisation des inhibiteurs de facteur de croissance épidermique |
US7173040B2 (en) | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
JP4974439B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体 |
EP1322635B1 (fr) | 2000-09-25 | 2006-03-22 | Janssen Pharmaceutica N.V. | Derives de quinoline et de quinazoline inhibant la farnesyl transferase comme inhibiteurs de farnesyl transferase |
AU2002220559A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
HUP0302167A3 (en) * | 2000-10-02 | 2010-03-29 | Janssen Pharmaceutica Nv | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them |
DE60139080D1 (de) | 2000-11-21 | 2009-08-06 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
US20040067968A1 (en) * | 2000-12-27 | 2004-04-08 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline |
US7129356B2 (en) | 2000-12-27 | 2006-10-31 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
US7015328B2 (en) | 2001-05-16 | 2006-03-21 | Cytovia, Inc. | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20030139332A1 (en) * | 2001-07-09 | 2003-07-24 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
WO2003051880A1 (fr) | 2001-12-19 | 2003-06-26 | Janssen Pharmaceutica N.V. | Utilisation de derives de quinoline 1,8-anneles substitues avec des triazoles lies par le carbone en tant qu'inhibiteurs de farnesyl transferase |
ES2287466T3 (es) | 2002-03-22 | 2007-12-16 | Janssen Pharmaceutica N.V. | Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa. |
JP4573533B2 (ja) * | 2002-03-29 | 2010-11-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用 |
ATE336496T1 (de) | 2002-04-15 | 2006-09-15 | Janssen Pharmaceutica Nv | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
US7528164B2 (en) | 2002-05-16 | 2009-05-05 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1513515A2 (fr) | 2002-05-16 | 2005-03-16 | Cytovia, Inc. | 4h-chromenes substitues, 2h-chromenes substitues, chromans substitues et analogues utilises comme activateurs de caspases et inducteurs de l apoptose, et utilisation de ces composes |
US20040186160A1 (en) * | 2002-12-13 | 2004-09-23 | Sugen, Inc. | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors |
EA008501B1 (ru) * | 2002-12-19 | 2007-06-29 | Пфайзер Инк. | 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний |
RS53118B (en) | 2003-02-26 | 2014-06-30 | Sugen Inc. | AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
TW200504057A (en) * | 2003-02-27 | 2005-02-01 | Chugai Pharmaceutical Co Ltd | Benzothiophene derivative |
KR20060097105A (ko) * | 2003-07-22 | 2006-09-13 | 얀센 파마슈티카 엔.브이. | C-fms 키나아제 저해제로서의 퀴놀리논 유도체 |
JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Gtpアーゼ阻害剤および使用方法 |
JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | シヌクレイノパチーを治療する方法 |
EP1744751A4 (fr) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | Traitement des synucleinopathies |
WO2005089515A2 (fr) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Procedes de traitement des synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
ES2355923T3 (es) * | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
EP1786777A1 (fr) * | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases |
KR100859891B1 (ko) * | 2004-08-26 | 2008-09-23 | 화이자 인코포레이티드 | 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물 |
WO2006041900A2 (fr) * | 2004-10-07 | 2006-04-20 | Cytovia, Inc. | N-aryl-1h-pyrazolo[3,4-b]quinolin-4-amines substitues et analogues utilises comme activateurs de caspases et inducteurs de l'apoptose |
CA2617056A1 (fr) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Inhibiteurs de gtpase et methodes d'utilisation et structure cristalline de la gtpase rac-1 |
PE20080035A1 (es) | 2005-09-07 | 2008-01-30 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
DK1926996T3 (da) | 2005-09-20 | 2012-01-23 | Osi Pharmaceuticals Llc | Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere |
WO2007075923A2 (fr) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Traitement de formes de synucleinopathie |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
NZ574580A (en) | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
CA2687973C (fr) * | 2007-05-23 | 2015-04-07 | Allergan, Inc. | Composes d'((heteroaryle bicyclique) imidazolyle) methyle heteroaryle utilises en tant qu'agonistes des recepteurs adrenergiques |
WO2008144623A1 (fr) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Lactames cycliques destinés au traitement du glaucome ou de la pression intraoculaire élevée |
US8129356B2 (en) * | 2007-10-01 | 2012-03-06 | Vanderbilt University | Bmx mediated signal transduction in irradiated vascular endothelium |
WO2009151683A2 (fr) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
AU2009313927A1 (en) * | 2008-11-13 | 2010-05-20 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2393814A1 (fr) * | 2009-02-09 | 2011-12-14 | SuperGen, Inc. | Inhibiteurs pyrrolopyrimidinyle de l'axi kinase |
WO2010099139A2 (fr) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Thérapie anti-cancer combinée |
EP2400990A2 (fr) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo |
WO2010099364A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
WO2010099138A2 (fr) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
EP2401614A1 (fr) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2542893A2 (fr) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (fr) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
WO2013152252A1 (fr) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Polythérapie antinéoplasique |
WO2013166043A1 (fr) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rajeunissement de cellules précurseurs |
EP2909192B1 (fr) | 2012-10-16 | 2017-05-17 | Janssen Pharmaceutica NV | Modulateurs de ror-gamma-t de type quinolinyle à liaison méthylène |
BR112015008515A2 (pt) | 2012-10-16 | 2017-07-04 | Janssen Pharmaceutica Nv | moduladores de ror t de quinolinila ligada à heteroarila |
SG11201502935VA (en) | 2012-10-16 | 2015-09-29 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
RU2019119893A (ru) | 2013-03-14 | 2019-08-09 | Толеро Фармасьютикалз, Инк. | Ингибиторы jak2 и alk2 и способы их использования |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
CN105848483A (zh) | 2013-10-15 | 2016-08-10 | 詹森药业有限公司 | RORγt 的喹啉基调节剂 |
ES2770727T3 (es) | 2013-10-15 | 2020-07-02 | Janssen Pharmaceutica Nv | Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
CN108601752A (zh) | 2015-12-03 | 2018-09-28 | 安吉奥斯医药品有限公司 | 用于治疗mtap缺失型癌症的mat2a抑制剂 |
CN108003150A (zh) * | 2016-10-31 | 2018-05-08 | 河南工业大学 | 4-杂芳基喹啉酮衍生物的制备方法及其应用 |
AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
WO2021155006A1 (fr) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2732531A1 (de) * | 1977-07-19 | 1979-02-01 | Hoechst Ag | Imidazolcarbonsaeuren und deren derivate |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US5136085A (en) * | 1990-11-28 | 1992-08-04 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
US5053543A (en) * | 1990-11-28 | 1991-10-01 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
TR199800825T2 (xx) * | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri. |
EP0988038B1 (fr) * | 1997-06-02 | 2002-08-14 | Janssen Pharmaceutica N.V. | Derives d'(imidazol-5-yl)methyle-2-quinolinone comme inhibiteurs de la proliferation des cellules des muscles lisses |
SK2442001A3 (en) | 1998-08-27 | 2002-10-08 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof |
TR200201297T2 (tr) * | 1999-02-11 | 2002-06-21 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. |
-
2000
- 2000-02-04 TR TR2002/01297T patent/TR200201297T2/xx unknown
- 2000-02-04 CA CA002362394A patent/CA2362394C/fr not_active Expired - Fee Related
- 2000-02-04 AU AU21248/00A patent/AU2124800A/en not_active Abandoned
- 2000-02-04 PL PL00349839A patent/PL349839A1/xx not_active Application Discontinuation
- 2000-02-04 CN CN00803668A patent/CN1340051A/zh active Pending
- 2000-02-04 EA EA200100766A patent/EA200100766A1/ru unknown
- 2000-02-04 BR BR0008202-3A patent/BR0008202A/pt not_active IP Right Cessation
- 2000-02-04 EP EP00901292A patent/EP1150973B1/fr not_active Expired - Lifetime
- 2000-02-04 JP JP2000598494A patent/JP4090200B2/ja not_active Expired - Fee Related
- 2000-02-04 OA OA1200100212A patent/OA11833A/en unknown
- 2000-02-04 EE EEP200100425A patent/EE200100425A/xx unknown
- 2000-02-04 AT AT00901292T patent/ATE297916T1/de not_active IP Right Cessation
- 2000-02-04 WO PCT/IB2000/000121 patent/WO2000047574A1/fr active IP Right Grant
- 2000-02-04 SK SK1100-2001A patent/SK11002001A3/sk unknown
- 2000-02-04 ES ES00901292T patent/ES2243228T3/es not_active Expired - Lifetime
- 2000-02-04 ID IDW00200101724A patent/ID29584A/id unknown
- 2000-02-04 AP APAP/P/2001/002241A patent/AP2001002241A0/en unknown
- 2000-02-04 TR TR2002/01296T patent/TR200201296T2/xx unknown
- 2000-02-04 CZ CZ20012910A patent/CZ20012910A3/cs unknown
- 2000-02-04 HU HU0105231A patent/HUP0105231A3/hu unknown
- 2000-02-04 KR KR1020017010187A patent/KR20010102073A/ko not_active Application Discontinuation
- 2000-02-04 DE DE60020812T patent/DE60020812T2/de not_active Expired - Lifetime
- 2000-02-04 IL IL14430700A patent/IL144307A0/xx unknown
- 2000-02-09 DZ DZ000021A patent/DZ3009A1/fr active
- 2000-02-09 US US09/501,163 patent/US6258824B1/en not_active Expired - Fee Related
- 2000-02-09 HN HN2000000019A patent/HN2000000019A/es unknown
- 2000-02-09 TN TNTNSN00028A patent/TNSN00028A1/fr unknown
- 2000-02-09 CO CO00008430A patent/CO5140097A1/es unknown
- 2000-02-09 MA MA25905A patent/MA26718A1/fr unknown
- 2000-02-10 GT GT200000014A patent/GT200000014A/es unknown
- 2000-02-10 PA PA20008490601A patent/PA8490601A1/es unknown
- 2000-02-10 SV SV2000000020A patent/SV2001000020A/es not_active Application Discontinuation
- 2000-02-10 PE PE2000000103A patent/PE20001464A1/es not_active Application Discontinuation
- 2000-02-10 AR ARP000100589A patent/AR028985A1/es not_active Application Discontinuation
-
2001
- 2001-04-17 US US09/836,026 patent/US6388092B2/en not_active Expired - Fee Related
- 2001-07-10 IS IS5997A patent/IS5997A/is unknown
- 2001-07-30 HR HR20010574A patent/HRP20010574A2/hr not_active Application Discontinuation
- 2001-08-08 ZA ZA200106520A patent/ZA200106520B/en unknown
- 2001-08-10 NO NO20013909A patent/NO20013909L/no not_active Application Discontinuation
- 2001-08-30 BG BG105860A patent/BG105860A/xx unknown
-
2002
- 2002-03-07 US US10/092,744 patent/US6710209B2/en not_active Expired - Fee Related
- 2002-05-31 HK HK02104118.7A patent/HK1042096A1/zh unknown
-
2004
- 2004-02-05 JP JP2004029709A patent/JP4216740B2/ja not_active Expired - Fee Related
- 2004-07-20 JP JP2004211298A patent/JP2005002124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ3009A1 (fr) | Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2963A1 (fr) | Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
DZ3042A1 (fr) | Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2880A1 (fr) | Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. | |
DZ3045A1 (fr) | Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2197A1 (fr) | Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2634A1 (fr) | Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant. | |
DZ1957A1 (fr) | Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2300A1 (fr) | Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2299A1 (fr) | Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ3020A1 (fr) | Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2198A1 (fr) | Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant. | |
DZ2457A1 (fr) | Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. | |
DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2773A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2128A1 (fr) | Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2758A1 (fr) | Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
CH689805A8 (fr) | Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant. | |
DZ2962A1 (fr) | Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant. | |
DZ3038A1 (fr) | Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant. |